As STAT’s Helen Branswell writes, mRNA vaccines are the fastest to make and the easiest to mass produce.

The obesity medicine field has gained a new entrant, with AbbVie licensing an experimental drug from a Danish company.

Its deal with AbbVie is a collaboration and option-to-license ... principal accounting officer and treasurer. Don't miss out on Boston-area life science news. Subscribe to the Morning Edition ...

If consummated, the marriage will also give AbbVie access to Aliada's MODEL platform for delivering large-molecule drugs across the blood-brain barrier (BBB). The Boston biotech said the platform ...

AbbVie has finally claimed FDA approval for its advanced Parkinson's disease therapy Vyalev, 18 months after the US regulator turned it down with a request for more data. Now, Vyalev (foscarbidopa ...

AbbVie is joining the chase for new obesity drugs, but rather than getting a me-too GLP-1 drug, the pharmaceutical giant is landing rights to a clinical-stage molecule that goes after two novel ...

AbbVie has signed a licensing deal with Danish-based Gubra to develop an obesity drug, marking the North Chicago company's first foray into the obesity market. Gubra will receive $350 million ...